ENT1 Inhibitor
Acute Kidney Injury
PreclinicalActive
Key Facts
About RapaFusyn Pharmaceuticals
RapaFusyn Pharmaceuticals is a private, preclinical-stage biotech based in San Diego, founded in 2018. The company has developed a proprietary platform to create RapaGlues, a unique modality of non-degrading molecular glues that harness the FKBP12 chaperone to target intractable proteins. With a pipeline of eight disclosed programs across oncology and immunology & inflammation, the company is advancing its lead program towards IND and recently secured a significant $44 million Series A financing to fuel its platform and pipeline development.
View full company profileTherapeutic Areas
Other Acute Kidney Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| AKI Program | Keli Therapeutics | Clinical Trial Launch |
| VANADIS® (AKI) | CFM Pharma | Pre-clinical |